RxDoctor Payments Data

John Oconnor, MD

Family Medicine · Marathon, FLNPI 1659465458

Payments from drug & device makers

$927in general payments, 2019–2025

Across 34 payments — averaging $27.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$194
  • AbbVie$180
  • Pfizer$173
  • Merck$137
  • Takeda Pharmaceuticals U.S.A., Inc.$60
  • GSK$56
  • plus $126 from 5 others

What the payments were for

  • Food & beverage$927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$927 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$189,238
Medicare patients
820
Services billed
2,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$31,790
MounjaroTirzepatide20$23,321
EliquisApixaban17$21,541
OzempicSemaglutide18$16,651
Combivent RespimatIpratropium/Albuterol Sulfate19$9,671
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$5,361
Quetiapine Fumarate16$2,460
Gabapentin64$1,433
Albuterol Sulfate HfaAlbuterol Sulfate73$1,265
Cefdinir58$1,176
Nitroglycerin17$1,000
Alprazolam76$972
Acetaminophen-CodeineAcetaminophen With Codeine69$942
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort20$896
Prednisone201$867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$26$41,46145 claims
Lilly USA, LLCMounjaro$194$23,32120 claims
PfizerEliquis$173$21,54117 claims
Novo NordiskOzempic$18$16,65118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Marathon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →